P&T
Our
Other
Journal
MediMedia Managed Markets

 

 

November 2006

Whether a person is likely to develop diabetes, cancer, schizophrenia, or stroke will be reasonably well predicted, and tests can also determine whether a patient will respond to a given therapy. That's the good part.
Maureen Glabman
Paying for medical group practice redesign can significantly enhance the quality of care for chronically ill patients, and perhaps lower long-term costs
Martin Sipkoff
There are plenty of ways that confidential data can escape your control, and the consequences can be major. Can you trust your employees?
Ed Silverman
Germany has been able to enroll more than a million people with type 2 diabetes in DM programs through legislation that created incentives for physicians and insurers
Heinz Nagel, MD ; Thomas Baehring, PhD ; Werner A. Scherbaum, MD, PhD
This CMO of a pharmacy benefits manager wrestles with some of insurance's most taxing issues. Price, of course. And here come biologics!
Patrick Mullen



Departments
Viewpoint
Arthur Lazarus, MD, MBA
Legislation & Regulation
Despite an array of economically and politically strong advocates, a bill to beef up health savings accounts has stirred significant opposition
John Carroll
Medication Management
Many insurers may not consider insomnia a serious health problem, but it costs employers a bundle in lowered productivity
Martin Sipkoff
Employer Update
Still, some are skeptical about punishing bad behavior. For one thing, it makes coverage more expensive for those who need it most.
Lola Butcher
Tomorrow's Medicine
The use of transgenic goats to produce a recombinant form of human antithrombin is much more efficient than using mammalian cell cultures
Thomas Morrow, MD